This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Mineralys Therapeutics’s 8K filing here.
Mineralys Therapeutics Company Profile
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
- Five stocks we like better than Mineralys Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- 3 Fintech Stocks With Good 2021 Prospects
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- What Does Downgrade Mean in Investing?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
